US20100041663A1 - Organic Compounds as Smo Inhibitors - Google Patents

Organic Compounds as Smo Inhibitors Download PDF

Info

Publication number
US20100041663A1
US20100041663A1 US12/503,565 US50356509A US2010041663A1 US 20100041663 A1 US20100041663 A1 US 20100041663A1 US 50356509 A US50356509 A US 50356509A US 2010041663 A1 US2010041663 A1 US 2010041663A1
Authority
US
United States
Prior art keywords
compound
mmol
dimethyl
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/503,565
Other languages
English (en)
Inventor
Feng He
Stefan Peukert
Karen Miller-Moslin
Naeem Yusuff
Zhuoliang Chen
Bharat Lagu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41130287&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100041663(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to US12/503,565 priority Critical patent/US20100041663A1/en
Publication of US20100041663A1 publication Critical patent/US20100041663A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, ZHUOLIANG, YUSUFF, NAEEM, HE, FENG, MILLER-MOSLIN, KAREN, PEUKERT, STEFAN, LAGU, BHARAT
Priority to US13/553,870 priority patent/US8481542B2/en
Priority to US13/905,686 priority patent/US9409871B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention includes compounds of formula (I) wherein R4 is C(O)OC 1-8 alkyl, CF 3 , C(O)OR6, C(O)NR6R8, C 1-8 haloalkyl, C 1-8 alkylOH, C(O)R6, SO 2 R6, C(O)NHC 1-8 alkylR6, C(CH 3 )(CH 3 )(OH), C(O)CH 3 , C(CH 2 )CH 3 , or C(CH 3 )(CH 2 OH)OH; and R6 and R8 are independently H, C 1-8 alkyl, C 1-8 alkenyl, C 3-14 cycloalkyl, a C 6-14 aryl group, a 5-14 membered heteroaryl group, or a 3-14 membered cycloheteroalkyl group.
  • the present invention includes compounds of formula (I) wherein R7 is
  • R6 and R8 are independently H, C 1-8 alkyl, such as methyl, ethyl, propyl, or butyl; C 2-8 alkenyl, such as alkenyl, propenyl; C 3-14 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; a C 6-14 aryl group, such as phenyl; a 5-14 membered heteroaryl group, such as pyridinyl or pyrimidinyl; a 3-14 membered cycloheteroalkyl group, such as morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl; C 1-8 haloalkyl, such as CF 3 ; C 1-8 alkylOH, C 1-8 alkoxy, such as methoxy or ethoxy; or two R6, or R6 and R8 on one atom can form a
  • R4 is C(O)CH 3 , C(O)NH-phenyl, C(O)OH, CF 3 , C(CH 3 )(CH 3 )OH, C(O)OCH 3 , CF 3 , or C(O)OCH 2 CH 3 .
  • the present invention includes compounds of formula (I) wherein R1 is
  • the present invention includes compounds of formula (I) wherein R4 is C(O)OC 1-8 alkyl, CF 3 , C(O)OR6, C(O)NR6R8, C 1-8 haloalkyl, C 1-8 alkylOH, C(O)R6, SO 2 R6, C(O)NHC 1-8 alkylR6, C(CH 3 )(CH 3 )(OH), C(O)CH 3 , CH 2 —CH 2 —CH 3 , or C(CH 3 )(CH 2 OH)OH.
  • R6 and R8 are independently H, methyl, ethyl, cyclopentyl, cyclohexyl, phenyl, pyridinyl, morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl, CF 3 , methoxy, two R6, or R6 and R8 on one atom can form a heteroatom containing ring, such as a 5-14 membered heteroaryl group, such as pyridinyl or pyrimidinyl; or a 3-14 membered cycloheteroalkyl group, such as piperidinyl or piperazinyl.
  • the present invention includes compounds of formula (I) wherein R4 is
  • Y is a bond, C 1-8 alkylene, such as methylene, ethylene, propylene —C(O)—, —C(O)O—, —CH(OH)—, or —C(O)NR10, where R10 is C 1-8 alkyl, such as methyl, ethyl, propyl, or butyl, or H.
  • R10 is C 1-8 alkyl, such as methyl, ethyl, propyl, or butyl, or H.
  • Y is a bond, methylene, —C(O)O—, or C(O)NH.
  • Y is a bond.
  • the methods of the present invention may employ compounds of the invention (e.g., a compound of Formula I) as formulated as pharmaceutical preparations comprising a pharmaceutically acceptable excipient or carrier, and said preparations may be administered to a patient to treat conditions involving unwanted cell proliferation such as cancers and/or tumors (such as medulloblastoma, basal cell carcinoma, etc.), and non-malignant hyperproliferative disorders.
  • compounds of the invention e.g., a compound of Formula I
  • pharmaceutical preparations comprising a pharmaceutically acceptable excipient or carrier
  • said preparations may be administered to a patient to treat conditions involving unwanted cell proliferation such as cancers and/or tumors (such as medulloblastoma, basal cell carcinoma, etc.), and non-malignant hyperproliferative disorders.
  • Hedgehog gain-of-function refers to an aberrant modification or mutation of a Ptc gene, Hedgehog gene, or smoothened gene, or a change (e.g., decrease) in the level of expression of such a gene, which results in a phenotype which resembles contacting a cell with a Hedgehog protein, e.g., aberrant activation of a Hedgehog pathway.
  • Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell.
  • polyadenylation signals are control sequences.
  • inhibitors refer to inhibitory molecules identified using in vitro and in vivo assays for Hh pathway function, e.g., Smo antagonists.
  • inhibitors and antagonists refer to compounds or agents that decrease signaling that occurs via the Hh pathway.
  • Inhibitors may be compounds that decrease, block, or prevent, signaling via this pathway.
  • malignant hyperproliferative disorder(s) includes but is not limited to cancers, neuronal proliferative disorders, bone marrow proliferative diseases and leukemias.
  • Perhaloalkyl groups i.e., alkyl groups wherein all of the hydrogen atoms are replaced with halogen atoms (e.g., CF 3 and C 2 F 5 ), are included within the definition of “haloalkyl.”
  • a C 1-10 haloalkyl group can have the formula —C i H 2i+1 ⁇ j X j , wherein X is F, Cl, Br, or I, i is an integer in the range of 1 to 10, and j is an integer in the range of 0 to 21, provided that j is less than or equal to 2i+1.
  • cycloalkyl refers to a non-aromatic carbocyclic group including cyclized alkyl, alkenyl, and alkynyl groups.
  • a cycloalkyl group can be monocyclic (e.g., cyclohexyl) or polycyclic (e.g., containing fused, bridged, and/or spiro ring systems), wherein the carbon atoms are located inside or outside of the ring system.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcaryl, adamantyl, and spiro[4.5]decanyl groups, as well as their homologs, isomers, and the like.
  • aryl refers to an aromatic monocyclic hydrocarbon ring system or a polycyclic ring system where at least one of the rings in the ring system is an aromatic hydrocarbon ring and any other aromatic rings in the ring system include only hydrocarbons.
  • a monocyclic aryl group can have from 6 to 14 carbon atoms and a polycyclic aryl group can have from 8 to 14 carbon atoms.
  • the aryl group can be covalently attached to the defined chemical structure at any carbon atom(s) that result in a stable structure.
  • isotopes suitable for inclusion in the compounds of the invention comprises isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
  • hydrogen such as 2 H and 3 H
  • carbon such as 11 C, 13 C and 14 C
  • chlorine such as 36 Cl
  • fluorine such as 18 F
  • iodine such as 123 I and 125 I
  • nitrogen such as 13 N and 15 N
  • oxygen such as 15 O, 17 O and 18 O
  • phosphorus such as 32 P
  • sulphur such as 35 S.
  • the methods of the present invention include the use of compounds of Formula I which agonize Ptc inhibition of Hedgehog signaling, such as by inhibiting activation of smoothened or downstream components of the signal pathway, in the regulation of repair and/or functional performance of a wide range of cells, tissues and organs, including normal cells, tissues, and organs, as well as those having the phenotype of Ptc loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function.
  • a compound of Formula I can inhibit activation of a Hedgehog pathway by binding to smoothened or its downstream proteins.
  • cells induce their neighbors to differentiate like themselves (homeogenetic induction); in other cases a cell inhibits its neighbors from differentiating like itself.
  • Cell interactions in early development may be sequential, such that an initial induction between two cell types leads to a progressive amplification of diversity.
  • inductive interactions occur not only in embryos, but in adult cells as well, and can act to establish and maintain morphogenetic patterns as well as induce differentiation.
  • N-terminal Hedgehog peptide As a result of the tethering, a high local concentration of N-terminal Hedgehog peptide is generated on the surface of the Hedgehog producing cells. It is this N-terminal peptide which is both necessary and sufficient for short- and long-range Hedgehog signaling activities.
  • lymphoma e.g., e.g., B-cell lymphoma, plasmoblastoma, plasmacytoma or CLL
  • the methods entail administering to the subject a pharmaceutical composition containing an effective amount of a compound of Formula I to inhibit the hedgehog signaling pathway.
  • the subject can be one who is diagnosed with lymphoma, with or without metastasis, at any stage of the disease (e.g., stage I to IV, Ann Arbor Staging System).
  • Lymphomas suitable for treatment with methods of the invention include but are not limited to Hodgkin's disease and non-Hodgkin's disease.
  • Non-Hodgkin's lymphoma includes but is not limited to (1) slow-growing lymphomas and lymphoid leukemia (e.g., chronic lymphocytic leukemia, small lymphocytic leukemia, lymphoplasmacytoid lymphoma, follicle center lymphoma, follicular small cleaved cell, follicular mixed cell, marginal zone B-cell lymphoma, hairy cell leukemia, plasmacytoma, myeloma, large granular lymphocyte leukemia, mycosis fungoides, szary syndrome); (2) moderately aggressive lymphomas and lymphoid leukemia (e.g., prolymphocytic leukemia, mantle cell lymphoma, follicle center lymphoma, follicular small cleaved cell, follicle center lymphoma, chronic lymphocytic leukemia/prolymphocytic leukemia, angiocentric lymphoma, an
  • Some of the therapeutic methods of the invention are particularly directed to treating lymphomas or myelomas which do not express Gli3.
  • Gli1 and Gli2 were expressed in all lymphomas, detectable Gli3 expression was present mainly in lymphomas which were resistant to Hh pathway inhibition by cyclopamine.
  • subjects with lymphomas can be first examined for expression of Gli3 in a lymphoma cell sample obtained from the subject.
  • Compounds of the invention are useful in the treatment of basal cell carcinoma (BCC or rodent ulcer), tumors of the adrenal glands arising from the cortex or the medulla part of the adrenal gland medulla, and ovarian tumors.
  • BCC basal cell carcinoma
  • tumors of the adrenal glands arising from the cortex or the medulla part of the adrenal gland medulla, and ovarian tumors.
  • dosages of the co-administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.
  • tumor treatment approaches including surgery, ionizing radiation, photodynamic therapy, implants, e.g. with corticosteroids, hormones, or they may be used as radiosensitizers.
  • implants e.g. with corticosteroids, hormones, or they may be used as radiosensitizers.
  • anti-inflammatory and/or antiproliferative treatment combination with anti-inflammatory drugs is included. Combination is also possible with antihistamine drug substances, bronchodilatatory drugs, NSAID or antagonists of chemokine receptors.
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • the free acid or free base forms of the compounds of the invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively.
  • a compound of the invention in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
  • a suitable base e.g., ammonium hydroxide solution, sodium hydroxide, and the like.
  • a compound of the invention in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc.).
  • the diastereomers can be separated by chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
  • the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions,” John Wiley And Sons, Inc., 1981.
  • the present invention is further exemplified, but not limited, by the following representative examples, which are intended to illustrate the invention and are not to be construed as being limitations thereon.
  • the structure of final products described herein can be confirmed by standard analytical methods, e.g., spectrometric and spectroscopic methods (e.g. MS, NMR). Abbreviations used are those conventional in the art.
  • Compounds are purified by standard methods, e.g. crystallization, flash chromatography or reversed phase HPLC.
  • reaction mixture is quenched with sat. aq. NH 4 Cl at ⁇ 78° C. and diluted with DCM.
  • the organic solution is washed with brine, dried over Na 2 SO 4 and concentrated to afford the crude material.
  • the resulting solid is purified by prep. HPLC, eluting with 10%-100% acetonitrile in water (both mobile phases modified by 3% n-PrOH). Fractions containing the desired product are combined and freeze-dried to afford a white solid (25 mg, 42%).
  • Example 54 is prepared from example 53 by addition of MeMgI as described for example 52. HR MS (m/z, MH+) meas. 434.2666, calc. 434.2668.
  • ketones XId can act as electrophiles for metallo-organic reagents such as R′′—Li to provide tertiary alcohol examples Il. Transformation of the hydroxyl group with fluorination reagants e.g. Deoxofluor yields further examples In.
  • Ketones X Id can be used in reductive amination reactions with amines and e.g. NaBH(OAc) 3 as reducing agent to yield examples Io.
  • Compound 30 is prepared from compound 10 and piperidine-4-carbonitrile following the procedure similar to what described for compound 3.
  • reaction mixture is allowed to stand for 3.5 h at room temperature and the reaction mixture is then concentrated under reduced pressure to yield a semi-solid which is recrystallized from heptane to yield crude product.
  • Purification by HPLC of the crude product with acetonitrile in water (from 10% to 100% with 3% 1-propanol) at 220 nm wavelength detection provides the desired product as off white powder (28 mg, 22%).
  • This compound as a TFA salt is prepared from compound 24 and 1,2,3,4-tetrahydro-isoquinoline following a procedure used in example 56.
  • Scheme 6 shows a general synthetic scheme for the preparation of compounds of Formula Ip.
  • Substituted 1,4-dichloropyridazines II can be reacted with organo-zinc reagents under palladium catalysis to form intermediates XII.
  • Displacement of the remaining chlorine with an piperazine in the presence of base yields compounds XIII.
  • substituent(s) Z the use of a N-protecting group might be required to block the reactivity of one of the piperazine nitrogens.
  • Intermediates XIII can react depending on the desired linker Y with R3-Cl in a nucleophilic displacement reaction under basic conditions, with R—CHO in a reductive amination with e.g.
  • 4,5-dimethyl-1,2-dihydro-pyridazine-3,6-dione (50 g, 357 mmol) is added to a 1 L flask and POCl 3 (250 mL) is slowly added. The suspension is stirred and heated to reflux and all starting material dissolves. After 2 h approximately 150 mL POCl 3 are removed under vacuum. The viscous, brown solution is poured in small portions slowly onto ice in a 1.5 L beaker under stirring. The orange suspension is neutralized with 28% aqueous ammonia under external cooling. The product is filtered with a Buchner funnel, washed with water and dried at 40° C. under vacuum to yield a off white powder (59 g, 93%).
  • the compound is prepared analogous to compound 37 starting from compound 36.
  • 3-chloro-6-(4-fluoro-benzyl)-4,5-dimethyl-pyridazine is prepared from 4,5-dimethyl-1,4-dichloro-pyridazine and para-fluoro benzyl zinc bromide.
  • Compound 45 is prepared analogous to compound 44 starting from of 1,4-dichloro-6,7-dihydro-5H-cyclopenta[d]pyridazine (compound 39) and para-fluorobenzyl zinc bromide.
  • Compound 55 is prepared as described above from piperazine and 3,6-dichloro-4,5-dimethyl-pyridazine.
  • Triethylamine (2.0 mL, 14.4 mmol, 2.9 eq) is added to a solution of 2-chloro-4-trifluoromethyl-pyrimidine-5-carboxylic acid methyl ester (1.25 g, 5.0 mmol, 1 eq), 3-chloro-4,5-dimethyl-6-((R)-3-methyl-piperazin-1-yl)-pyridazine (1.20 g, 5.0 mmol, 1 eq) in dichloromethane (40 mL) and the resulting solution is stirred at rt for 2 h.
  • the reaction mixture is diluted with dichloromethane (50 mL) and washed with water (25 mL), then brine (25 mL). The organic layer is separated, dried over sodium sulfate and concentrated under reduced pressure to a white residue. The desired compound is isolated by silica gel chromatography (10-75% EtOAc/heptane) as a white solid (1.83 g, 82%).
  • the compound is prepared in a similar fashion as described above.
  • Table 7 lists examples of compounds prepared by Grignard addition as described above:
  • example 116 40 mg, 0.10 mmol
  • HATU 73 mg, 0.14 mmole
  • diisopropylethyl amine 37 mg, 0.29 mmol
  • dimethylacetamide 1.5 ml
  • amine 0.14 mmole
  • HPLC acetonitrile/water (3% propanol), 30% ⁇ 100%) to afford the product (examples 133 to 140, 37% ⁇ 55%).
  • Table 8 lists examples of compounds prepared by amide formation as described above:
  • the reaction mixture is diluted with EtOAc (50 mL) and washed with water (2 ⁇ 10 mL) followed by brine (2 ⁇ 10 mL). The organic layer is dried over sodium sulfate and concentrated under reduced pressure to a white residue.
  • the desired compound is isolated by silica gel chromatography (CH 2 Cl 2 -20% MeOH/CH 2 Cl 2 ) as a white solid (43 mg, 79%).
  • Methyltriphenylphosphonium iodide (410 mg, 1.010 mmol) is added to THF (5.5 mL) and cooled to 5° C. Potassium tert-butoxide (1.1 mL, 1 M in THF, 1.1 mmol) is added dropwise and the reaction is stirred for 30 min.
  • 1-[(R)-4-(6-Benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyrazinyl-5′-yl]-ethanone (350 mg, 0.841 mmol) in THF (1.5 mL) is added to the reaction.
  • Table 9 lists examples of compounds prepared by amination as described above:
  • Scheme 7 shows a general synthetic scheme for the preparation of compounds of Formula Iq to Is.
  • Substituted chloro pyridazines IIIa can be reacted with acetonitrile under treatment with a strong base (e.g. LiHMDS) to form intermediates XIVa.
  • a strong base e.g. LiHMDS
  • Hydrolysis of the nitrile functionality provides acid intermediates XIVb and subsequent amid coupling with acid hydrazides yields intermediates XIVc.
  • Intermediates XIVa can be reacted with hydroxylamine and N,N-dimethylformamide-dimethylacetal to examples Iq or can provide tetrazole examples Ir by reaction with sodium azide followed by alkylation (e.g. bromides or iodides).
  • Intermediates XIVc can be condensed e.g. with triphenylphosphine to examples Is.
  • Acetic acid hydrazide (20.6 mg, 0.28 mmol) is added to a round-bottom flask under N 2 followed by DMF (5 mL). Diisopropylethylamine (0.25 mL) is added and the reaction is stirred for 30 min. ⁇ -4,5-Dimethyl-6-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyridazin-3-yl ⁇ -acetic acid (110 mg, 0.28 mmol) is added and the reaction is stirred for 1 h. HOBT (42 mg, 0.311 mmol) and HBTU (116.8 mg, 0.31 mmol) are added and the reaction is allowed to stir for 16 h. The crude reaction mixture is purified via flash chromatography on silica gel (0-30% methanol in dichloromethane) to afford the title compound (114 mg, 90%).
  • Methyl iodide (16 ⁇ L, 0.263 mmol) is added dropwise, and the reaction is stirred and allowed to warm to room temperature over 16 h. Cool back to 0° C. and add additional methyl iodide (24 ⁇ L, 0.395 mol). Allow reaction to warm to room temperature over 16 h. Concentrate reaction in vacuo and filter off solids. Wash with MeOH. Remaining solid is dissolved in H 2 O and TFA and is purified by HPLC (CH 3 CN/H 2 O) to afford the title compounds as a 57:43 mixture of regioisomers (22.2 mg, 20%).
US12/503,565 2008-07-18 2009-07-15 Organic Compounds as Smo Inhibitors Abandoned US20100041663A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/503,565 US20100041663A1 (en) 2008-07-18 2009-07-15 Organic Compounds as Smo Inhibitors
US13/553,870 US8481542B2 (en) 2008-07-18 2012-07-20 Pyridazinyl derivatives as smo inhibitors
US13/905,686 US9409871B2 (en) 2008-07-18 2013-05-30 Pyridazinyl derivatives as SMO inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8190008P 2008-07-18 2008-07-18
US12/503,565 US20100041663A1 (en) 2008-07-18 2009-07-15 Organic Compounds as Smo Inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/553,870 Division US8481542B2 (en) 2008-07-18 2012-07-20 Pyridazinyl derivatives as smo inhibitors

Publications (1)

Publication Number Publication Date
US20100041663A1 true US20100041663A1 (en) 2010-02-18

Family

ID=41130287

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/503,565 Abandoned US20100041663A1 (en) 2008-07-18 2009-07-15 Organic Compounds as Smo Inhibitors
US13/553,870 Active US8481542B2 (en) 2008-07-18 2012-07-20 Pyridazinyl derivatives as smo inhibitors
US13/905,686 Active 2030-02-06 US9409871B2 (en) 2008-07-18 2013-05-30 Pyridazinyl derivatives as SMO inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/553,870 Active US8481542B2 (en) 2008-07-18 2012-07-20 Pyridazinyl derivatives as smo inhibitors
US13/905,686 Active 2030-02-06 US9409871B2 (en) 2008-07-18 2013-05-30 Pyridazinyl derivatives as SMO inhibitors

Country Status (44)

Country Link
US (3) US20100041663A1 (ru)
EP (1) EP2318389B1 (ru)
JP (1) JP5492202B2 (ru)
KR (1) KR101312122B1 (ru)
CN (1) CN102143958B (ru)
AR (1) AR072816A1 (ru)
AU (1) AU2009272719B2 (ru)
BR (1) BRPI0916375A2 (ru)
CA (1) CA2731130C (ru)
CL (1) CL2011000101A1 (ru)
CO (1) CO6351727A2 (ru)
CR (1) CR20110014A (ru)
CU (1) CU24027B1 (ru)
CY (1) CY1114478T1 (ru)
DK (1) DK2318389T3 (ru)
DO (1) DOP2011000020A (ru)
EA (1) EA020710B1 (ru)
EC (1) ECSP11010764A (ru)
ES (1) ES2428100T3 (ru)
GE (1) GEP20125624B (ru)
GT (1) GT201100017A (ru)
HK (1) HK1155736A1 (ru)
HN (1) HN2011000193A (ru)
HR (1) HRP20130843T1 (ru)
IL (1) IL210494A (ru)
JO (1) JO2843B1 (ru)
MA (1) MA32485B1 (ru)
ME (1) ME01290B (ru)
MX (1) MX2011000721A (ru)
MY (1) MY149716A (ru)
NI (1) NI201100022A (ru)
NZ (1) NZ590483A (ru)
PE (1) PE20110153A1 (ru)
PL (1) PL2318389T3 (ru)
PT (1) PT2318389E (ru)
RS (1) RS52934B (ru)
SI (1) SI2318389T1 (ru)
SM (1) SMT201300114T1 (ru)
SV (1) SV2011003812A (ru)
TW (1) TWI431001B (ru)
UA (1) UA105181C2 (ru)
UY (1) UY31991A (ru)
WO (1) WO2010007120A1 (ru)
ZA (1) ZA201100205B (ru)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130500A1 (en) 2010-04-16 2011-10-20 Novartis Ag Formulations of a pyridazine bipyrazinyl
US20120232087A1 (en) * 2009-11-18 2012-09-13 Silvia Buonamici Methods and compositions for treating solid tumors and other malignancies
US8754113B2 (en) 2009-12-15 2014-06-17 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2017223474A1 (en) * 2016-06-23 2017-12-28 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
US11547709B2 (en) 2017-12-27 2023-01-10 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
WO2023101438A1 (ko) * 2021-11-30 2023-06-08 주식회사 헤지호그 Smo 인간 항체
US11891378B2 (en) 2017-12-27 2024-02-06 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
BRPI0911618A2 (pt) 2008-04-29 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de ftalazina dissubstituída.
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010013849A1 (ja) * 2008-08-01 2010-02-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
EP2617414A3 (en) * 2008-10-01 2013-11-06 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
EA018931B1 (ru) 2008-11-03 2013-11-29 Эли Лилли Энд Компани ДИЗАМЕЩЕННЫЕ ФТАЛАЗИНЫ-АНТАГОНИСТЫ СИГНАЛЬНОГО ПУТИ Hedgehog
CN102216285B (zh) 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
KR101335770B1 (ko) 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
MA34300B1 (fr) * 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
WO2012166241A1 (en) 2011-06-02 2012-12-06 Novartis Ag Biomarkers for hedgehog inhibitor therapy
SG11201502137YA (en) * 2012-09-21 2015-04-29 Agency Science Tech & Res A method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP3092236B1 (en) 2014-01-06 2020-08-26 Rhizen Pharmaceuticals S.A. Novel glutaminase inhibitors
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
MX2017015681A (es) 2015-06-04 2018-09-11 Pellepharm Inc Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos.
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
WO2018184978A1 (de) * 2017-04-05 2018-10-11 Bayer Cropscience Aktiengesellschaft 2-amino-5-oxyalkyl-pyrimidinderivate und deren verwendung zur bekämpfung unerwünschten pflanzenwachstums
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN114042069A (zh) * 2021-10-22 2022-02-15 陕西国际商贸学院 一种5-取代哒嗪-4-胺衍生物、制备方法和用途

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668207A (en) * 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
US4569934A (en) * 1984-10-09 1986-02-11 American Cyanamid Company Imidazo[1,2-b]pyridazines
US4734418A (en) * 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
US6689797B2 (en) * 2000-01-06 2004-02-10 Sanofi-Synthelabo Tetrahydropyridines, preparation method and pharmaceutical compositions containing same
US20060281712A1 (en) * 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
US20070010248A1 (en) * 2005-07-07 2007-01-11 Subrahmanyam Dravida Methods and devices for interworking of wireless wide area networks and wireless local area networks or wireless personal area networks
US20080318933A1 (en) * 2004-10-07 2008-12-25 Glaxo Group Limited 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders
US20090054410A1 (en) * 2006-02-07 2009-02-26 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
US20100029655A1 (en) * 2008-07-11 2010-02-04 Martin Robert Leivers Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
US20100112107A1 (en) * 2008-11-03 2010-05-06 Viva Pharmaceuticals Inc. Plant extract compositions for affecting sleep
US20100168093A1 (en) * 2006-04-28 2010-07-01 Miguel Angel Pericas-Brondo Substituted 3-amino-4 -hydroxy pyrrolidines compounds, their preparation and use as medicaments
US20100166655A1 (en) * 2006-03-15 2010-07-01 Janssen Pharmaceutica N.V. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
US7960556B2 (en) * 2006-11-22 2011-06-14 Nv Remynd Thiadiazole derivatives for the treatment of neuro-degenerative diseases
US20110190304A1 (en) * 2008-11-03 2011-08-04 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20110301162A1 (en) * 2008-08-04 2011-12-08 Amgen Inc. Aurora kinase modulators and methods of use
US20120010208A1 (en) * 2008-12-01 2012-01-12 Sanofi 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
US8193362B2 (en) * 2008-05-15 2012-06-05 Syngenta Crop Protection Llc Insecticidal compounds
US20120157466A1 (en) * 2006-12-22 2012-06-21 Qingbei Zeng Heterocyclic compounds with cxcr3 antagonist activity
US8236947B2 (en) * 2002-03-27 2012-08-07 Glaxo Group Limited Quinoline derivatives and their use as 5-HT6 ligands

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
DE2643753A1 (de) 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
FR2421900A1 (fr) 1977-03-17 1979-11-02 Sauba Lab Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
JP2544939B2 (ja) 1987-09-01 1996-10-16 大塚製薬株式会社 ベンゾヘテロ環誘導体
JPH0531271Y2 (ru) 1987-10-14 1993-08-11
JPH02193992A (ja) 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
JPH03106875A (ja) 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
US5849741A (en) 1994-08-09 1998-12-15 Eisai Co., Ltd. Fused pyridazine compounds
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2325140T3 (es) 1998-04-20 2009-08-26 ABBOTT GMBH & CO. KG Amidas sustituidas con heterociclos como inhibidores de la calpaina.
TW474933B (en) 1998-06-30 2002-02-01 Schering Corp Muscarinic antagonists
JP2002535365A (ja) 1999-01-28 2002-10-22 ブリストル−マイヤーズ スクイブ カンパニー 抗うつ性複素環化合物
JP2000281660A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd キナゾリン誘導体
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
PL203116B1 (pl) 1999-05-04 2009-08-31 Schering Corp Piperazynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
ES2165274B1 (es) 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
WO2001083481A1 (fr) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazopyridine
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
ES2172436B1 (es) 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
AU2002247847A1 (en) 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
JP4929547B2 (ja) 2001-09-03 2012-05-09 コニカミノルタホールディングス株式会社 アゾメチン化合物、アゾメチン化合物と金属イオン含有化合物との混合物、感熱転写記録材料、カラートナー
ES2292812T3 (es) 2001-10-19 2008-03-16 Ortho-Mcneil Pharmaceutical, Inc. 2-fenil benzimidazol e imidazo-(4,5)-piridinas como inhibidores de cds1/chk2 y coadyuvantes para quimioterapia o radioterapia en el tratamiento del cancer.
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
CN1751038A (zh) 2003-02-24 2006-03-22 艾尼纳制药公司 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗
EP2316826A1 (en) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutics agents
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
JP5335191B2 (ja) 2003-08-22 2013-11-06 デンドレオン コーポレイション Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
EA201890903A9 (ru) 2004-09-02 2021-11-10 Дженентек, Инк. Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
CA2629814C (en) * 2005-11-14 2013-12-31 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
AR059962A1 (es) 2006-03-21 2008-05-14 Schering Corp Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3
CA2650704A1 (en) * 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
AU2007243280A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
CA2658417A1 (en) 2006-07-14 2008-01-17 Schering Corporation Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
BRPI0720789A2 (pt) 2006-12-14 2014-03-11 Syngenta Participations Ag Herbicidas
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200900391A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
PE20081882A1 (es) 2007-03-15 2008-12-27 Schering Corp Derivados de piridazinona utiles como inhibidores de glucano sintasa
ATE506343T1 (de) 2007-03-15 2011-05-15 Hoffmann La Roche Malonamide als orexin-antagonisten
DK2137162T3 (en) 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
WO2009035568A1 (en) * 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CA2729313C (en) 2008-07-03 2016-08-30 Janssen Pharmaceutica Nv Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists
US8216547B2 (en) 2008-07-18 2012-07-10 Janssen Pharmaceutica Nv Radiolabelled TRP M8 receptor ligands
FR2933982A1 (fr) 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
BRPI0916464A2 (pt) 2008-07-18 2018-06-12 Sanofi-Aventis derivados triazolo(4,3-a) piridina, o respectivo processo de preparo, a respectiva aplicação como medicamentos, composições farmacêuticas e utilização notadamente como inibidores de met
CN102099339A (zh) 2008-07-18 2011-06-15 武田药品工业株式会社 苯并氮杂衍生物及其作为组胺h3拮抗剂的用途
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
PE20110572A1 (es) 2008-07-18 2011-08-25 Sanofi Aventis DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO INHIBIDORES DE MET
EP2617414A3 (en) 2008-10-01 2013-11-06 Novartis AG Smoothened antagonism for the treatment of hedgehog pathway-related disorders
KR101335770B1 (ko) * 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668207A (en) * 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
US4569934A (en) * 1984-10-09 1986-02-11 American Cyanamid Company Imidazo[1,2-b]pyridazines
US4734418A (en) * 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
US6689797B2 (en) * 2000-01-06 2004-02-10 Sanofi-Synthelabo Tetrahydropyridines, preparation method and pharmaceutical compositions containing same
US8236947B2 (en) * 2002-03-27 2012-08-07 Glaxo Group Limited Quinoline derivatives and their use as 5-HT6 ligands
US20080318933A1 (en) * 2004-10-07 2008-12-25 Glaxo Group Limited 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders
US20060281712A1 (en) * 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
US20070010248A1 (en) * 2005-07-07 2007-01-11 Subrahmanyam Dravida Methods and devices for interworking of wireless wide area networks and wireless local area networks or wireless personal area networks
US20090054410A1 (en) * 2006-02-07 2009-02-26 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
US20100166655A1 (en) * 2006-03-15 2010-07-01 Janssen Pharmaceutica N.V. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
US20100168093A1 (en) * 2006-04-28 2010-07-01 Miguel Angel Pericas-Brondo Substituted 3-amino-4 -hydroxy pyrrolidines compounds, their preparation and use as medicaments
US7960556B2 (en) * 2006-11-22 2011-06-14 Nv Remynd Thiadiazole derivatives for the treatment of neuro-degenerative diseases
US20120157466A1 (en) * 2006-12-22 2012-06-21 Qingbei Zeng Heterocyclic compounds with cxcr3 antagonist activity
US8193362B2 (en) * 2008-05-15 2012-06-05 Syngenta Crop Protection Llc Insecticidal compounds
US20100029655A1 (en) * 2008-07-11 2010-02-04 Martin Robert Leivers Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
US20110301162A1 (en) * 2008-08-04 2011-12-08 Amgen Inc. Aurora kinase modulators and methods of use
US20100112107A1 (en) * 2008-11-03 2010-05-06 Viva Pharmaceuticals Inc. Plant extract compositions for affecting sleep
US20110190304A1 (en) * 2008-11-03 2011-08-04 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20120010208A1 (en) * 2008-12-01 2012-01-12 Sanofi 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"The Effects of Smoothened(Smo) siRNA on Expression of Smo Gene and Proliferation, Apoptosis of Lovo Cells," http://www.tumorres.com/tumor-marker/29544.htm, downloaded 4/4/2012 *
Chemical Book, CUR61414 Basic Information, 2008, http://www.chemicalbook.com/ProductChemicalPropertiesCB31565488_EN.htm, downloaded 9-20-2012 *
Kimura, et al., Cancer Cell, 13, 249-260, 2008 *
Lee, et all, Oncogene, 2007, 26, 6442-6447 *
Martin, et al., Cancer Biology & Therapy 4:7, 728-733, July 2005 *
Ng, et al., Nature Reviews: Cancer, 11, 07-2011, 493-501 *
Rudin, et al., New England J. of Medicine, 361: 12, 09-17-2009, 1173-1178 *
Ruiz-Heiland, et al., Ann Rheum Dis. 2012 Mar;71(3):400-7. Epub 2012 Jan 10 *
Schairer, et al., 53rd ASH Annual Meeting & Exposition, Dec. 10-13, 2011 *
Tauchi, Arthritis Research & Therapy 2012, Volume 14 Suppl 1, 17 *
Wikipedia, Cyclopamine, last modified 06-05-2012, http://en.wikipedia.org/wiki/Cyclopamine, downloaded 9-20-2012 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120232087A1 (en) * 2009-11-18 2012-09-13 Silvia Buonamici Methods and compositions for treating solid tumors and other malignancies
US8754113B2 (en) 2009-12-15 2014-06-17 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011130500A1 (en) 2010-04-16 2011-10-20 Novartis Ag Formulations of a pyridazine bipyrazinyl
WO2017223474A1 (en) * 2016-06-23 2017-12-28 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
KR20190022620A (ko) * 2016-06-23 2019-03-06 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 판토테네이트 키나제의 소분자 조절제
US10899734B2 (en) 2016-06-23 2021-01-26 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
KR102459256B1 (ko) 2016-06-23 2022-10-25 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 판토테네이트 키나제의 소분자 조절제
US11547709B2 (en) 2017-12-27 2023-01-10 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
US11891378B2 (en) 2017-12-27 2024-02-06 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
WO2023101438A1 (ko) * 2021-11-30 2023-06-08 주식회사 헤지호그 Smo 인간 항체

Also Published As

Publication number Publication date
CL2011000101A1 (es) 2011-07-01
ECSP11010764A (es) 2011-02-28
MX2011000721A (es) 2011-02-24
IL210494A0 (en) 2011-03-31
SMT201300114T1 (it) 2013-11-08
CY1114478T1 (el) 2016-10-05
NZ590483A (en) 2012-07-27
CA2731130A1 (en) 2010-01-21
EA201100192A1 (ru) 2011-08-30
CN102143958B (zh) 2013-12-18
CA2731130C (en) 2016-03-29
SV2011003812A (es) 2011-07-05
SI2318389T1 (sl) 2013-10-30
US20130261299A1 (en) 2013-10-03
PT2318389E (pt) 2013-09-20
JP5492202B2 (ja) 2014-05-14
JO2843B1 (en) 2014-09-15
AU2009272719B2 (en) 2012-06-28
US20120289507A1 (en) 2012-11-15
PL2318389T3 (pl) 2013-11-29
CN102143958A (zh) 2011-08-03
HN2011000193A (es) 2014-06-09
AR072816A1 (es) 2010-09-22
ME01290B (me) 2013-06-20
ES2428100T3 (es) 2013-11-05
US9409871B2 (en) 2016-08-09
AU2009272719A1 (en) 2010-01-21
BRPI0916375A2 (pt) 2018-02-06
UY31991A (es) 2010-02-26
CO6351727A2 (es) 2011-12-20
DK2318389T3 (da) 2013-09-30
JP2011528329A (ja) 2011-11-17
EP2318389A1 (en) 2011-05-11
DOP2011000020A (es) 2011-02-15
TW201008929A (en) 2010-03-01
WO2010007120A1 (en) 2010-01-21
GT201100017A (es) 2013-08-29
RS52934B (en) 2014-02-28
CU24027B1 (es) 2014-08-28
IL210494A (en) 2015-08-31
UA105181C2 (ru) 2014-04-25
MA32485B1 (fr) 2011-07-03
KR20110036620A (ko) 2011-04-07
CR20110014A (es) 2011-08-26
HK1155736A1 (en) 2012-05-25
EP2318389B1 (en) 2013-06-19
TWI431001B (zh) 2014-03-21
GEP20125624B (en) 2012-08-27
ZA201100205B (en) 2011-10-26
PE20110153A1 (es) 2011-03-14
CU20110011A7 (es) 2011-12-28
NI201100022A (es) 2011-08-05
EA020710B1 (ru) 2015-01-30
HRP20130843T1 (en) 2013-10-11
KR101312122B1 (ko) 2013-09-26
US8481542B2 (en) 2013-07-09
MY149716A (en) 2013-10-14

Similar Documents

Publication Publication Date Title
US9409871B2 (en) Pyridazinyl derivatives as SMO inhibitors
US10472342B2 (en) Compounds and compositions for inhibition of FASN
CA2733533C (en) Hedgehog pathway modulators
US8536168B2 (en) Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
AU2007276788A1 (en) Compounds and compositions as hedgehog signaling pathway modulators
KR20140138865A (ko) 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
JP2007508290A (ja) ＧＳＫ−３阻害剤としての置換２Ｈ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HE, FENG;PEUKERT, STEFAN;MILLER-MOSLIN, KAREN;AND OTHERS;SIGNING DATES FROM 20090706 TO 20090722;REEL/FRAME:026563/0474

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION